{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T20:50:44Z","timestamp":1781383844222,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10549-026-07912-w","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:47:00Z","timestamp":1771235220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer"],"prefix":"10.1007","volume":"216","author":[{"given":"Aixa E.","family":"Soyano Muller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn N.","family":"Goodridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianxing","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Khakpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Catherine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Laronga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avan J.","family":"Armaghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Kiluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zena","family":"Jameel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung T.","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1","key":"7912_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"3 Suppl","key":"7912_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/cncr.11126","volume":"97","author":"JC Keen","year":"2003","unstructured":"Keen JC, Davidson NE (2003) The biology of breast carcinoma. Cancer 97(3 Suppl):825\u2013833","journal-title":"Cancer"},{"issue":"9","key":"7912_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol 34(9):927\u2013935","journal-title":"J Clin Oncol"},{"issue":"17","key":"7912_CR4","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis MJ et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol 29(17):2342\u20132349","journal-title":"J Clin Oncol"},{"issue":"9","key":"7912_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P et al (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382(9):810\u2013821","journal-title":"N Engl J Med"},{"issue":"3","key":"7912_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387(3):217\u2013226","journal-title":"N Engl J Med"},{"issue":"6","key":"7912_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14712598.2024.2370395","volume":"24","author":"I Schlam","year":"2024","unstructured":"Schlam I et al (2024) Checkpoint inhibition for early-stage hormone receptor-positive breast cancer. Expert Opin Biol Ther 24(6):511\u2013520","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"7912_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso F et al (2025) Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)\/HER2(-) breast cancer: a randomized phase 3 trial. Nat Med 31(2):442\u2013448","journal-title":"Nat Med"},{"key":"7912_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.582863","volume":"10","author":"C Shuai","year":"2020","unstructured":"Shuai C et al (2020) Estrogen receptor downregulates expression of PD-1\/PD-L1 and infiltration of CD8(+) T cells by inhibiting IL-17 signaling transduction in breast cancer. Front Oncol 10:582863","journal-title":"Front Oncol"},{"issue":"6\u20137","key":"7912_CR10","first-page":"398","volume":"44","author":"J Wang","year":"2009","unstructured":"Wang J et al (2009) Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis. Exp Gerontol 44(6\u20137):398\u2013405","journal-title":"Exp Gerontol"},{"issue":"2","key":"7912_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10549-010-0887-y","volume":"121","author":"M Mello-Grand","year":"2010","unstructured":"Mello-Grand M et al (2010) Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat 121(2):399\u2013411","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7912_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201846","volume":"13","author":"S Kurozumi","year":"2018","unstructured":"Kurozumi S et al (2018) Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. PLoS ONE 13(8):e0201846","journal-title":"PLoS ONE"},{"key":"7912_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174279","author":"X Ge","year":"2022","unstructured":"Ge X et al (2022) Phase II study combining pembrolizumab with aromatase inhibitor in patients with metastatic hormone receptor positive breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14174279","journal-title":"Cancers (Basel)"},{"issue":"15_suppl","key":"7912_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2020.38.15_suppl.504","volume":"38","author":"CX Ma","year":"2020","unstructured":"Ma CX et al (2020) ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. J Clin Oncol 38(15_suppl):504\u2013504","journal-title":"J Clin Oncol"},{"issue":"11","key":"7912_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring LM et al (2016) Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol 2(11):1477\u20131486","journal-title":"JAMA Oncol"},{"issue":"2","key":"7912_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259\u2013271","journal-title":"Ann Oncol"},{"issue":"3","key":"7912_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.31557\/APJCP.2022.23.3.1091","volume":"23","author":"NH Amin","year":"2022","unstructured":"Amin NH et al (2022) Expression of PD-L1 in early-stage invasive breast carcinoma and its relation to tumor-infiltrating lymphocytes. Asian Pac J Cancer Prev 23(3):1091\u20131102","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07912-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:50:46Z","timestamp":1771843846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07912-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7912"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07912-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}